Global drug giants double down on China amid push for self-reliant supply chains
www.scmp.com
Multinationals are building self-reliant supply chains in China to insulate local markets from potential trade disruptions, say analysts.

AstraZeneca said it would establish drug manufacturing facilities in Guangzhou and Shanghai as well as a separate innovation centre in Shanghai, joining a group of foreign players building new plants in China amid geopolitical tensions. The moves are part of a US$15 billion commitment the British firm pledged to make in the world’s second-largest drug market through 2030, unveiled during UK Prime Minister Keir Starmer’s visit to Beijing in January. China’s manufacturing capabilities, integrated…

From China - South China Morning Post via This RSS Feed.